{"id":19315,"date":"2018-04-09T11:25:22","date_gmt":"2018-04-09T09:25:22","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=19315"},"modified":"2022-03-10T05:48:08","modified_gmt":"2022-03-10T04:48:08","slug":"9-april-2018-dermapharm-continued-profitable-growth-in-2017","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/en\/9-april-2018-dermapharm-continued-profitable-growth-in-2017\/","title":{"rendered":"<span id=\"2018\" class=\"Postdate\">9. April 2018<\/span> | Dermapharm continued profitable growth in 2017"},"content":{"rendered":"<p>[et_pb_section admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;Zeile&#8221; make_fullwidth=&#8221;off&#8221; use_custom_width=&#8221;off&#8221; width_unit=&#8221;on&#8221; use_custom_gutter=&#8221;off&#8221; custom_padding=&#8221;||0px|&#8221; padding_mobile=&#8221;off&#8221; allow_player_pause=&#8221;off&#8221; parallax=&#8221;off&#8221; parallax_method=&#8221;off&#8221; make_equal=&#8221;off&#8221; parallax_1=&#8221;off&#8221; parallax_method_1=&#8221;off&#8221; parallax_2=&#8221;off&#8221; parallax_method_2=&#8221;off&#8221; column_padding_mobile=&#8221;on&#8221;][et_pb_column type=&#8221;1_2&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<style>\n.zur\u00fcckbutton:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #00225f;\n    margin-right: 7px;\n}\n.zur\u00fcckbutton:hover:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #d85710;\n    margin-right: 7px;\n}\n<\/style>\n<h1 style=\"text-align: justify;\">Corporate news<\/h1>\n<p> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243;][et_pb_image admin_label=&#8221;Bild&#8221; src=&#8221;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei\u00df_2-6.png&#8221; show_in_lightbox=&#8221;off&#8221; url_new_window=&#8221;off&#8221; use_overlay=&#8221;off&#8221; animation=&#8221;off&#8221; sticky=&#8221;off&#8221; align=&#8221;right&#8221; force_fullwidth=&#8221;off&#8221; always_center_on_mobile=&#8221;on&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221; saved_tabs=&#8221;all&#8221;]<\/p>\n<h1>Dermapharm continued profitable growth in 2017<\/h1>\n<ul>\n<li>Revenue in 2017 up 4.9% from last year to EUR 467 million <\/li>\n<li>Adjusted EBITDA up 9.7% from last year to EUR 113 million \u00bb Adjusted EBITDA margin of 24.2% kept positive trend \u00bb Basis laid for continued profitable growth in 2018 and beyond<\/li>\n<\/ul>\n<p><strong>Gr\u00fcnwald, April 9, 2018<\/strong> \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany with a growing international presence, published its unaudited preliminary IFRS financial figures for fiscal year 2017 today. They indicate that Dermapharm has continued its profitable growth course. The highly profitable business area branded pharmaceuticals and other healthcare products made a significant contribution to revenue and earnings growth. The year also saw important steps taken to continue the company\u2019s success story. <\/p>\n<p>Revenue rose on a preliminary basis by 4.9% to EUR 467 million in fiscal year 2017 (previous year: EUR 445 million). Dermapharm\u2019s 2017 earnings before interest, taxes, depreciation and amortization (EBITDA) significantly improved, disproportionate to total revenue. Dermapharm increased its EBITDA by 9.7% to EUR 113 million (previous year: EUR 103 million), adjusted for one-time costs for IPO preparations of EUR 2.7 million. Dermapharm therefore once again improved its overall profitability in 2017, achieving an adjusted EBITDA margin of 24.2% at Group level (previous year: 23.1%). Unadjusted EBITDA amounted to EUR 110 million, 6.8% higher than last year, with an unadjusted EBITDA margin of 23.6%. <\/p>\n<p>Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, comments: \u201c2017 was a successful year. Dermapharm continued to grow profitably as planned while consistently advancing the development of new products and acquiring with bite away\u00ae and Herpotherm\u00ae two very promising medical devices that we will use particularly for international marketing. We also acquired Trommsdorff and Strathmann, two attractive companies that will expand our product portfolio in a meaningful direction. Coupled with our IPO in February 2018, this development provides a very strong basis for continuing our success story into the future.\u201d The acquisition of Strathmann, a producer of over-the-counter pharmaceuticals (OTC), took place in December 2017 while that of pharmaceutical producer Trommsdorff and its portfolio of 23 different prescription drugs and OTC products was completed in January 2018. <\/p>\n<p>Dermapharm is also constantly striving to develop and launch new pharmaceuticals and other healthcare products on the market to expand its product portfolio. Dermapharm\u2019s product pipeline currently comprises over 40 ongoing development projects with new products for all areas including vitamins\/minerals\/enzymes, dermatologicals, systemic corticoids, women\u2019s healthcare and ophtalmologicals. The pipeline comprises 28 medications and other healthcare products which are expected to be marketable by 2023. In view of its international presence, Dermapharm plans to introduce select products such as bite away\u00ae and Herpotherm\u00ae in Italy, Spain, the UK and the Benelux countries. Subsidiaries in Italy and the UK have already been established and sales managers appointed. Preparations for the expansion of Dermapharm\u2019s main site in Brehna and the construction of a new production facility in Neumark am Wallersee, Austria, are also proceeding according to plan. <\/p>\n<p>Dermapharm will publish its final figures for fiscal year 2017 as well as a detailed forecast for the current fiscal year with its complete Annual Report 2017 on April 27, 2018. <\/p>\n<p>Revenue and EBITDA 2017 with previous year comparison (IFRS, preliminary) <\/p>\n<table class=\"tableizer-table\">\n<thead>\n<tr class=\"tableizer-firstrow\">\n<th>in EUR millions <\/th>\n<th>2017 <\/th>\n<th>2016 <\/th>\n<th>Change <\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Group revenue <\/td>\n<td>467 <\/td>\n<td>445 <\/td>\n<td>+4.9% <\/td>\n<\/tr>\n<tr>\n<td>Adjusted Group EBITDA* <\/td>\n<td>113 <\/td>\n<td>103 <\/td>\n<td>+9.7% <\/td>\n<\/tr>\n<tr>\n<td>Adjusted EBITDA margin* (in %) <\/td>\n<td>24.2 <\/td>\n<td>23.1 <\/td>\n<td>+1.1pp <\/td>\n<\/tr>\n<tr>\n<td>Group EBITDA <\/td>\n<td>110 <\/td>\n<td>103 <\/td>\n<td>+6.8% <\/td>\n<\/tr>\n<tr>\n<td>EBITDA margin (in %) <\/td>\n<td>23.6 <\/td>\n<td>23.1 <\/td>\n<td>+0.5pp <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>* Adjusted for one-off costs of EUR 2.7 million for IPO preparations<\/p>\n<p>Company profile:<br \/>\nDermapharm \u2013 Pharmaceutical Excellence \u201cMade in Germany\u201d<br \/>\nDermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Gr\u00fcnwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company\u2019s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 200 active pharmaceutical ingredients, which are reflected in a broad assortment of products. This assortment makes the company unique. In addition to Germany, the company\u2019s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm\u2019s business model also includes a parallel import business, which operates under the \u201caxicorp\u201d brand. Based on revenues, Dermapharm was among the top four parallel import companies in Germany in 2016. <\/p>\n<p>With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on three strategic growth drivers: in-house development of new products, increase of its international footprint and further acquisitions. These include the acquisition of the pharmaceuticals manufacturer and distributor Trommsdorff in January 2018, whose portfolio includes the well-known brands Keltican\u00ae forte and Tromcardin\u00ae complex. <\/p>\n<p>Contact<br \/>\ncometis AG<br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611-20585528<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nEmail: ir@dermapharm.de<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/e_180409_CN_Preliminary_Figures_2017.pdf\" target=\"_blank\" rel=\"noopener\">Post as PDF<\/a><\/div>\n<style>\n.leseprobe-archiv {\n    color: #00225f !important;\n    border-color: #00225f;\n    position: relative;\n    padding: 0.3em 1em;\n    border: 1px solid;\n    -webkit-border-radius: 3px;\n    -moz-border-radius: 3px;\n    border-radius: 3px;\n   -webkit-transition: all 0.2s;\n    -moz-transition: all 0.2s;\n    transition: all 0.2s;\n    padding:10px;\n    width: 19%;\n    text-align: center;\n    margin-right: 10px;\n    float:left;\n}\n.leseprobe-archiv:hover {\n    background-color: #eee;\n    border-color: #ffffff;\n    cursor: pointer;\n}\n<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Corporate news to the archive Dermapharm continued profitable growth in 2017 Revenue in 2017 up 4.9% from last year to EUR 467 million Adjusted EBITDA up 9.7% from last year to EUR 113 million \u00bb Adjusted EBITDA margin of 24.2% kept positive trend \u00bb Basis laid for continued profitable growth in 2018 and beyond Gr\u00fcnwald, [&hellip;]<\/p>\n","protected":false},"author":24813,"featured_media":54374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section admin_label=\"section\"][et_pb_row admin_label=\"Zeile\" make_fullwidth=\"off\" use_custom_width=\"off\" width_unit=\"on\" use_custom_gutter=\"off\" custom_padding=\"||0px|\" padding_mobile=\"off\" allow_player_pause=\"off\" parallax=\"off\" parallax_method=\"off\" make_equal=\"off\" parallax_1=\"off\" parallax_method_1=\"off\" parallax_2=\"off\" parallax_method_2=\"off\" column_padding_mobile=\"on\"][et_pb_column type=\"1_2\"][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<style>\r\n.zur\u00fcckbutton:before {\r\n    display: inline-block;\r\n    font-family: \"ETmodules\";\r\n    content: \"4a\";\r\n    color: #00225f;\r\n    margin-right: 7px;\r\n}\r\n.zur\u00fcckbutton:hover:before {\r\n    display: inline-block;\r\n    font-family: \"ETmodules\";\r\n    content: \"4a\";\r\n    color: #d85710;\r\n    margin-right: 7px;\r\n}\r\n<\/style>\r\n<h1 style=\"text-align: justify;\">Ad-hoc<\/h1> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/veroeffentlichungsarchiv-dermapharm\">zum Archiv<\/a>\r\n\r\n[\/et_pb_text][\/et_pb_column][et_pb_column type=\"1_2\"][et_pb_image admin_label=\"Bild\" src=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei\u00df_2-6.png\" show_in_lightbox=\"off\" url_new_window=\"off\" use_overlay=\"off\" animation=\"off\" sticky=\"off\" align=\"right\" force_fullwidth=\"off\" always_center_on_mobile=\"on\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n\r\n\r\n[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\"row\"][et_pb_column type=\"4_4\"][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\" saved_tabs=\"all\"]\r\n\r\n<h1>Dermapharm Holding SE: setzt 2017 profitables Wachstum fort<\/h1>\r\n\u00a0\r\n\r\n\u00bb Umsatz 2017 um 4,9 % gegen\u00fcber Vorjahr auf 467 Mio. EUR gestiegen\r\n\u00bb Bereinigtes EBITDA um 9,7 % gegen\u00fcber Vorjahr erh\u00f6ht auf 113 Mio. EUR\r\n\u00bb Bereinigte EBITDA-Marge weiter verbessert auf 24,2 %\r\n\u00bb Basis f\u00fcr weiteres profitables Wachstum 2018 und dar\u00fcber hinaus gelegt\r\n\r\n<strong>Gr\u00fcnwald, 9. April 2018 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender<\/strong>\r\n<strong>Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in<\/strong>\r\n<strong>Deutschland mit wachsender internationaler Pr\u00e4senz, ver\u00f6ffentlicht heute ihre<\/strong>\r\n<strong>ungepr\u00fcften vorl\u00e4ufigen IFRS-Finanzkennzahlen f\u00fcr das Gesch\u00e4ftsjahr 2017. Demnach<\/strong>\r\n<strong>befindet sich Dermapharm weiter auf profitablem Wachstumskurs. Ganz wesentlich zum<\/strong>\r\n<strong>Umsatz- und Ergebniswachstum trug der hochprofitable Bereich Markenarzneimittel und<\/strong>\r\n<strong>andere Gesundheitsprodukte bei. Gleichzeitig wurden wichtige Schritte unternommen, um<\/strong>\r\n<strong>die bisherige Erfolgsgeschichte auch in Zukunft fortzuf\u00fchren.<\/strong>\r\n\r\nDer Umsatz stieg auf vorl\u00e4ufiger Basis im Gesch\u00e4ftsjahr 2017 um 4,9 % auf 467 Mio. EUR (Vorjahr: 445 Mio. EUR). Deutlich \u00fcberproportional zum Gesamtumsatz verbesserte Dermapharm 2017 das Ergebnis vor Zinsen, Steuern und Abschreibungen (EBITDA). Das um Einmalkosten im Zusammenhang mit der Vorbereitung der B\u00f6rsennotierung in H\u00f6he von 2,7 Mio. EUR bereinigte EBITDA steigerte Dermapharm um 9,7 % auf 113 Mio. EUR (Vorjahr: 103 Mio. EUR). Insgesamt verbesserte Dermapharm damit 2017 die Profitabilit\u00e4t weiter und erzielte auf Konzernebene eine bereinigte EBITDA-Marge von 24,2 % (Vorjahr: 23,1 %). Das unbereinigte EBITDA betrug 110 Mio. EUR, was einer Steigerung von 6,8 % gegen\u00fcber dem Vorjahr bzw. einer unbereinigten EBITDA-Marge von 23,6 % entspricht. Dr. Hans-Georg Feldmeier, Vorstandsvorsitzender der Dermapharm Holding SE, kommentiert: \u201e2017 war ein erfolgreiches Jahr. Dermapharm ist planm\u00e4\u00dfig weiter profitabel gewachsen, wir haben die Entwicklung neuer Produkte konsequent vorangetrieben und mit bite away\u00ae und Herpotherm\u00ae zwei sehr vielversprechende Medizinprodukte erworben, die wir insbesondere auch in der internationalen Vermarktung nutzen werden. Zudem haben wir mit Trommsdorff und Strathmann zwei attraktive Unternehmen \u00fcbernommen, die unser Produktportfolio sinnvoll erweitern. Dies zusammen mit unserem B\u00f6rsengang im Februar 2018 sind eine sehr gute Basis, um unsere Erfolgsgeschichte auch in Zukunft weiter fortf\u00fchren zu k\u00f6nnen.\u201c Die Akquisition von Strathmann, einem Hersteller rezeptfreier Arzneimittel (over the counter pharmaceuticals (\u201eOTC\u201d)), erfolgte im Dezember 2017. Die \u00dcbernahme des Arzneimittelproduzenten Trommsdorff und dessen Portfolio mit 23 verschiedenen verschreibungspflichtigen Arzneimitteln und OTC-Produkten wurde im Januar 2018 abgeschlossen. Um ihr Produktportfolio zu erweitern, ist Dermapharm zudem stetig bestrebt, weitere Arzneimittel und andere Gesundheitsprodukte zu entwickeln und in den Markt einzuf\u00fchren. Derzeit umfasst die Produktpipeline von Dermapharm mehr als 40 laufende Entwicklungsprojekte mit neuen Produkten f\u00fcr alle Produktbereiche Vitamine\/Mineralstoffe\/Enzyme, Dermatika, Systemische Kortikoide, Frauengesundheit und Augentherapeutika. Diese Pipeline umfasst 28 Arzneimittel und andere Gesundheitsprodukte die voraussichtlich bis 2023 vermarktbar sein werden. Im Hinblick auf ihre internationale Pr\u00e4senz plant Dermapharm, ausgew\u00e4hlte Produkte wie etwa bite away\u00ae und Herpotherm\u00ae in Italien, Spanien, Gro\u00dfbritannien sowie den Benelux-Staaten einzuf\u00fchren. Tochtergesellschaften in Italien und Gro\u00dfbritannien wurden bereits gegr\u00fcndet und Vertriebsmanager eingestellt. Und auch die Vorbereitungen f\u00fcr die Erweiterungen des Hauptstandorts von Dermapharm in Brehna sowie der Neubau einer Produktionsst\u00e4tte in Neumark am Wallersee, \u00d6sterreich, verlaufen planm\u00e4\u00dfig. \r\nDie endg\u00fcltigen Zahlen f\u00fcr das Gesch\u00e4ftsjahr 2017 sowie eine detaillierte Prognose f\u00fcr das laufende Gesch\u00e4ftsjahr wird Dermapharm mit dem vollst\u00e4ndigen Gesch\u00e4ftsbericht 2017 am 27. April 2018 \r\n\r\n<table class=\"tableizer-table\">\r\n<thead><tr class=\"tableizer-firstrow\"><th>in Mio. EUR <\/th><th>Q1\/2018 <\/th><th>Q1\/2017 <\/th><th>Ver\u00e4nderung <\/th><\/tr><\/thead><tbody>\r\n <tr><td>Konzernumsatz <\/td><td>137,5 <\/td><td>118,1 <\/td><td>+ 16,4% <\/td><\/tr>\r\n <tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><td>79,5 <\/td><td>55,6 <\/td><td>+ 43,0% <\/td><\/tr>\r\n <tr><td>Parallelimportgesch\u00e4ft <\/td><td>58,0 <\/td><td>62,5 <\/td><td>- 7,2% <\/td><\/tr>\r\n <tr><td>\u00dcberleitung \/ Konzernholding <\/td><td>- <\/td><td>- <\/td><td>- <\/td><\/tr>\r\n <tr><td>Bereinigtes\u00b9 Konzern-EBITDA <\/td><td>36,2 <\/td><td>28,9 <\/td><td>+ 25,3% <\/td><\/tr>\r\n <tr><td>Bereinigte\u00b9 EBITDA-Marge (in %) <\/td><td>26,3 <\/td><td>24,5 <\/td><td>+ 1,8pp <\/td><\/tr>\r\n <tr><td>Konzern-EBITDA <\/td><td>35,5 <\/td><td>28,9 <\/td><td>+ 22,8% <\/td><\/tr>\r\n <tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><\/tr>\r\n <tr><td>bereinigt\u00b9 <\/td><td>34,5 <\/td><td>27,3 <\/td><td>+ 26,4% <\/td><\/tr>\r\n <tr><td>unbereinigt <\/td><td>33,8 <\/td><td>27,3 <\/td><td>+ 23,8% <\/td><\/tr>\r\n <tr><td>Parallelimportgesch\u00e4ft <\/td><td>2,7 <\/td><td>1,6 <\/td><td>+ 68,8% <\/td><\/tr>\r\n <tr><td>\u00dcberleitung \/ Konzernholding <\/td><td>-1,0 <\/td><td>- <\/td><td>- <\/td><\/tr>\r\n <tr><td>EBITDA-Marge (in %) <\/td><td>25,8 <\/td><td>24,5 <\/td><td>+ 1,3pp <\/td><\/tr>\r\n <tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><\/tr>\r\n <tr><td>bereinigt\u00b9 <\/td><td>43,3 <\/td><td>49,1 <\/td><td>- 5,8pp <\/td><\/tr>\r\n <tr><td>unbereinigt <\/td><td>42,4 <\/td><td>49,1 <\/td><td>- 6,7pp <\/td><\/tr>\r\n <tr><td>Parallelimportgesch\u00e4ft <\/td><td>4,7 <\/td><td>2,6 <\/td><td>+ 2,1pp <\/td><\/tr>\r\n<\/tbody><\/table>\r\n\r\n<strong>Unternehmensprofil:<\/strong>\r\n<strong>Dermapharm - Pharmazeutische Exzellenz \"Made in Germany\"<\/strong>\r\nDermapharm ist ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte M\u00e4rkte in Deutschland. Die 1991 gegr\u00fcndete Gesellschaft hat ihren Sitz in Gr\u00fcnwald bei M\u00fcnchen und ihren Hauptproduktionsstandort in Brehna bei Leipzig. Das integrierte Gesch\u00e4ftsmodell der Gesellschaft umfasst die hausinterne Entwicklung, eigene Produktion sowie den Vertrieb von Arzneimitteln und anderen Gesundheitsprodukten f\u00fcr ausgew\u00e4hlte M\u00e4rkte durch einen pharmazeutisch geschulten Au\u00dfendienst. Dermapharm verf\u00fcgt \u00fcber rund 900 Arzneimittelzulassungen f\u00fcr mehr als 200 pharmazeutische Wirkstoffe, die sich in einem breiten Produktsortiment widerspiegeln. Dieses Sortiment macht das Unternehmen unverwechselbar. Zu den Kernm\u00e4rkten der Gesellschaft geh\u00f6ren derzeit neben Deutschland auch \u00d6sterreich und die Schweiz. Die Gesellschaft plant, ihre internationale Pr\u00e4senz weiter auszubauen. Das Gesch\u00e4ftsmodell von Dermapharm umfasst \u00fcberdies ein Parallelimportgesch\u00e4ft, das unter der Marke \u201eaxicorp\u201c betrieben wird. Ausgehend vom Umsatz geh\u00f6rte Dermapharm hier 2017 zu den vier umsatzst\u00e4rksten Parallelimporteuren in Deutschland. Mit einer konsequenten F&E-Strategie und zahlreichen erfolgreichen Produkt- und Firmen\u00fcbernahmen in den vergangenen 25 Jahren hat Dermapharm ihre Gesch\u00e4ftsaktivit\u00e4ten kontinuierlich optimiert und neben organischem Wachstum f\u00fcr externe Wachstumsimpulse gesorgt. Diesen profitablen Wachstumskurs beabsichtigt Dermapharm auch in Zukunft fortzuf\u00fchren. Dabei setzt das Unternehmen auf drei Wachstumstreiber: die hausinterne Entwicklung neuer Produkte, die Ausweitung der internationalen Pr\u00e4senz sowie weitere Akquisitionen. Dazu z\u00e4hlt der Erwerb des Arzneimittelherstellers und -vermarkters Trommsdorff im Januar 2018, zu dessen Portfolio beispielsweise die bekannten Marken Keltican\u00ae forte und Tromcardin\u00ae complex geh\u00f6ren.\r\n\r\n<strong>Kontakt<\/strong>\r\ncometis AG\r\nClaudius Krause\r\nTel.: +49 (0)611 \u2013 205855-28\r\nFax: +49 (0)611 \u2013 205855-66\r\nE-Mail: ir@dermapharm.de\r\n\r\n[\/et_pb_text][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/d_180409_CN_Vorlaeufige_Zahlen_2017.pdf\" target=\"_blank\">Beitrag als PDF<\/a><\/div>\r\n<style>\r\n.leseprobe-archiv {\r\n    color: #00225f !important;\r\n    border-color: #00225f;\r\n    position: relative;\r\n    padding: 0.3em 1em;\r\n    border: 1px solid;\r\n    -webkit-border-radius: 3px;\r\n    -moz-border-radius: 3px;\r\n    border-radius: 3px;\r\n   -webkit-transition: all 0.2s;\r\n    -moz-transition: all 0.2s;\r\n    transition: all 0.2s;\r\n    padding:10px;\r\n    width: 19%;\r\n    text-align: center;\r\n    margin-right: 10px;\r\n    float:left;\r\n}\r\n.leseprobe-archiv:hover {\r\n    background-color: #eee;\r\n    border-color: #ffffff;\r\n    cursor: pointer;\r\n}\r\n<\/style>\r\n\r\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[326,448],"tags":[489],"class_list":["post-19315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-489"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>9. April 2018 | Dermapharm continued profitable growth in 2017 - cometis AG<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9. April 2018 | Dermapharm continued profitable growth in 2017 - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Corporate news to the archive Dermapharm continued profitable growth in 2017 Revenue in 2017 up 4.9% from last year to EUR 467 million Adjusted EBITDA up 9.7% from last year to EUR 113 million \u00bb Adjusted EBITDA margin of 24.2% kept positive trend \u00bb Basis laid for continued profitable growth in 2018 and beyond Gr\u00fcnwald, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-09T09:25:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T04:48:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"172\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"9. April 2018 | Dermapharm continued profitable growth in 2017\",\"datePublished\":\"2018-04-09T09:25:22+00:00\",\"dateModified\":\"2022-03-10T04:48:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/\"},\"wordCount\":1032,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2018\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/\",\"name\":\"9. April 2018 | Dermapharm continued profitable growth in 2017 - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2018-04-09T09:25:22+00:00\",\"dateModified\":\"2022-03-10T04:48:08+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"width\":172,\"height\":174,\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9. April 2018 | Dermapharm continued profitable growth in 2017 - cometis AG","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"9. April 2018 | Dermapharm continued profitable growth in 2017 - cometis AG","og_description":"Corporate news to the archive Dermapharm continued profitable growth in 2017 Revenue in 2017 up 4.9% from last year to EUR 467 million Adjusted EBITDA up 9.7% from last year to EUR 113 million \u00bb Adjusted EBITDA margin of 24.2% kept positive trend \u00bb Basis laid for continued profitable growth in 2018 and beyond Gr\u00fcnwald, [&hellip;]","og_url":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/","og_site_name":"cometis AG","article_published_time":"2018-04-09T09:25:22+00:00","article_modified_time":"2022-03-10T04:48:08+00:00","og_image":[{"width":172,"height":174,"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"9. April 2018 | Dermapharm continued profitable growth in 2017","datePublished":"2018-04-09T09:25:22+00:00","dateModified":"2022-03-10T04:48:08+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/"},"wordCount":1032,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2018"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/","url":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/","name":"9. April 2018 | Dermapharm continued profitable growth in 2017 - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2018-04-09T09:25:22+00:00","dateModified":"2022-03-10T04:48:08+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/9-april-2018-dermapharm-holding-se-setzt-2017-profitables-wachstum-fort\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":172,"height":174,"caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/19315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=19315"}],"version-history":[{"count":0,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/19315\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media\/54374"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=19315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=19315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=19315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}